Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$4.05B |
| 2 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.61B |
| 3 |
Tesla
TSLA
|
+$636M |
| 4 |
TSMC
TSM
|
+$604M |
| 5 |
iShares Bitcoin Trust
IBIT
|
+$330M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$1.25B |
| 2 |
Apple
AAPL
|
+$1.13B |
| 3 |
Microsoft
MSFT
|
+$988M |
| 4 |
Meta Platforms (Facebook)
META
|
+$572M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$570M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 94.1% |
| 2 | Technology | 1.55% |
| 3 | Consumer Discretionary | 0.95% |
| 4 | Financials | 0.77% |
| 5 | Healthcare | 0.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
11026
Fennec Pharmaceuticals
FENC
$430M
| $184K | ﹤0.01% |
30,258
+17,826
| +143% | +$114K |
|
11027
NetSol Technologies
NTWK
$49M
| $184K | ﹤0.01% |
76,125
-17,860
| -19% | -$45.3K |
|
|
DAO
11028
Youdao
DAO
$2.01B
| $184K | ﹤0.01% |
24,096
+11,356
| +89% | +$93.6K |
|
11029
CALL
Citizens
CIA
$194M
| $184K | ﹤0.01% |
40,400
+17,900
| +80% | +$86.3K |
|
11030
PUT
Lightwave Logic
LWLG
$846M
| $184K | ﹤0.01% |
178,400
-113,300
| -39% | -$177K |
|
|
QIPT
11031
DELISTED
Quipt Home Medical
QIPT
| $184K | ﹤0.01% |
78,816
-8,911
| -10% | -$24.4K |
|
|
MAPS
11032
DELISTED
WM TECHNOLOGY INC A
MAPS
| $183K | ﹤0.01% |
162,224
+51,387
| +46% | +$68.5K |
|
11033
PUT
First Watch Restaurant Group
FWRG
$772M
| $183K | ﹤0.01% |
+11,000
| New | +$212K |
|
11034
PUT
inTEST
INTT
$142M
| $183K | ﹤0.01% |
26,200
+9,700
| +59% | +$80.5K |
|
11035
CALL
Treace Medical Concepts
TMCI
$302M
| $183K | ﹤0.01% |
21,800
+8,900
| +69% | +$80K |
|
11036
Nomura Holdings
NMR
$30.1B
| $183K | ﹤0.01% |
29,707
+10,133
| +52% | +$64.5K |
|
11037
American Vanguard Corp
AVD
$64.6M
| $183K | ﹤0.01% |
41,508
-223
| -0.5% | -$1.14K |
|
11038
PUT
Aegon
AEG
$13.6B
| $183K | ﹤0.01% |
27,700
-12,700
| -31% | -$81.2K |
|
11039
Instil Bio
TIL
$51.4M
| $182K | ﹤0.01% |
+10,511
| New | +$218K |
|
11040
Neumora Therapeutics
NMRA
$261M
| $182K | ﹤0.01% |
182,341
+146,060
| +403% | +$250K |
|
|
RSVR
11041
Reservoir Media
RSVR
$637M
| $182K | ﹤0.01% |
23,896
+12,177
| +104% | +$95.5K |
|
11042
CALL
Bakkt Inc
BKKT
$347M
| $182K | ﹤0.01% |
21,000
-498,600
| -96% | -$8.52M |
|
|
AVGX
11043
CALL
Defiance Daily Target 2X Long AVGO ETF
AVGX
$172M
| $182K | ﹤0.01% |
+12,300
| New | +$314K |
|
11044
CALL
Sagimet Biosciences
SGMT
$656M
| $182K | ﹤0.01% |
55,800
+33,400
| +149% | +$140K |
|
11045
Perspective Therapeutics
CATX
$355M
| $182K | ﹤0.01% |
85,330
+58,891
| +223% | +$177K |
|
11046
PUT
Rigel Pharmaceuticals
RIGL
$868M
| $182K | ﹤0.01% |
+10,100
| New | +$205K |
|
|
DHC
11047
PUT
Diversified Healthcare Trust
DHC
$1.85B
| $182K | ﹤0.01% |
75,700
+8,500
| +13% | +$21K |
|
11048
PUT
Columbia Financial
CLBK
$1.2B
| $182K | ﹤0.01% |
12,100
-7,500
| -38% | -$116K |
|
11049
Medifast
MED
$136M
| $181K | ﹤0.01% |
13,458
-148,332
| -92% | -$2.23M |
|
11050
PUT
Mitsubishi UFJ Financial
MUFG
$258B
| $181K | ﹤0.01% |
+13,300
| New | +$171K |
|
Similar funds
Jeff Yass's Q1 2025 Portfolio in Review
As of Q1 2025, Jeff Yass held 13,842 positions worth $586B, down 12% from $663B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Jeff Yass's Q1 2025 filing shows 1,775 new, 5,712 increased, 4,842 reduced and 1,482 closed positions. Its largest new stake was Brookfield Asset Management: 1,775,684 shares worth $86M. The largest sale was Invesco QQQ Trust, an estimated $1.25B.
By sector, the portfolio is most concentrated in Miscellaneous at 94% of assets, up from 93% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jeff Yass's largest Q1 2025 buy was Brookfield Asset Management: 1,775,684 shares worth $86M.
- Jeff Yass added most to State Street SPDR S&P 500 ETF Trust in Q1 2025, an estimated $4.05B increase.
- Jeff Yass's biggest Q1 2025 reduction was Invesco QQQ Trust, cutting an estimated $1.25B.
- Jeff Yass fully exited Inari Medical, Inc. Common Stock in Q1 2025, selling an estimated $24M.
- Jeff Yass's ten largest holdings make up 28% of its $586B portfolio in Q1 2025.
- Jeff Yass opened 1,775 new positions and closed 1,482 in Q1 2025.
- Jeff Yass's portfolio value fell 12% quarter-over-quarter to $586B.
Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.